menu
    • menu

    Company profile for SystImmune

    NEW Drugs in Dev: 6
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    SystImmune Inc. is a biopharmaceutical company focused on developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs) for the treatment of cancer. Our objective is to create biologics that work through systematic intervention on tumor microenvironments, that directly attack the tumor and activate the immune system to attack the tumor.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SystImmuneUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    15318 NE 95th St, Redmond, WA 98052
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://systimmune.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/systimmune/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biokin To Present At J.P. Morgan Healthcare Conference
    Biokin To Present At J.P. Morgan Healthcare Conference

    13 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biokin-to-present-at-jp-morgans-44th-annual-healthcare-conference-302659846.html

    PR NEWSWIRE
    13 Jan 2026
    Share Share
    Systimmune Reports Iza-Bren Success In BL-B01D1-303 Trial
    Systimmune Reports Iza-Bren Success In BL-B01D1-303 Trial

    19 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/systimmune-announces-iza-bren-meets-one-of-the-dual-primary-endpoints-in-the-bl-b01d1-303-trial-in-recurrent-or-metastatic-npc-patients-with-results-presented-as-a-late-breaking-oral-presentation-at-esmo-302588317.html

    PR NEWSWIRE
    19 Oct 2025
    Share Share
    Systimmune, Bristol Myers Squibb Unveil Global Phase I Results
    Systimmune, Bristol Myers Squibb Unveil Global Phase I Results

    17 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/systimmune-inc-and-bristol-myers-squibb-announce-first-global-phase-i-results-of-iza-bren-an-egfr-x-her3-bispecific-antibody-drug-conjugate-in-patients-with-advanced-solid-tumors-at-esmo-2025-302586896.html

    PR NEWSWIRE
    17 Oct 2025
    Share Share
    Systimmune To Showcase Data On Izalontamab Brengitecan & BL-M07D1
    Systimmune To Showcase Data On Izalontamab Brengitecan & BL-M07D1

    24 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/systimmune-inc-to-present-new-clinical-data-on-izalontamab-brengitecan-and-bl-m07d1-highlighting-strength-of-differentiated-antibody-drug-conjugate-adc-platform-302564945.html

    PR NEWSWIRE
    24 Sep 2025
    Share Share
    SystImmune Unveils New iza-bren Data for NSCLC at WCLC Congress
    SystImmune Unveils New iza-bren Data for NSCLC at WCLC Congress

    02 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/systimmune-inc-to-present-new-iza-bren-izalontamab-brengitecan-data-in-non-small-cell-lung-cancer-at-wclc-congress-2025-302542350.html

    PR NEWSWIRE
    02 Sep 2025
    Share Share
    U.S. FDA grants Breakthrough Therapy for Izalontamab Brengitecan
    U.S. FDA grants Breakthrough Therapy for Izalontamab Brengitecan

    18 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/izalontamab-brengitecan-egfrxher3-adc-granted-breakthrough-therapy-designation-by-us-fda-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer-302531369.html

    PR NEWSWIRE
    18 Aug 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search